1-10 of 77 results
Five things to know about investment in healthtech
The use of technology to improve or create efficiencies in the delivery of healthcare services, and to progress precision/preventative models is continuing to drive investment in Healthtech. Here are our 'top 5' tips for investing in Healthtech. ...
Allens advises Bain Capital on $959M proposed acquisition of Estia
The signing of the scheme implementation agreement progresses Bain Capital's five-month pursuit of Estia, having made an initial non-binding and indicative proposal in March. 'We are delighted to ...
Healthcare property - an emerging trend for investors
While investing in healthcare-related property is generally similar to investing in other classes of property, in this Insight we explain some key differences and risks that investors need to be aware of. ...
From Sleeping Giant to Awakening Giant – ANDHealth Report on the Australian Digital Health Sector
ANDHealth recently launched its detailed report on the state of the Australian digital health sector, The Awakening Giant: The Rise of Australia's Evidence-Based Digital Health Sector. In this Insight we summarise some of the key takeaways from the report, including key trends and challenges for the Australian market. ...
Aged care reform: back on the agenda
In this Insight, we focus in on the key regulatory enforcement and provider governance reforms to be implemented under the Royal Commission Response Bill and the implications for approved providers. ...
Software-based medical devices: key regulatory requirements, IP considerations and data privacy implications
Software is increasingly being used as a medical device and in medical devices. It is crucial that businesses understand the regulations that can apply to software-based medical devices, the IP considerations if they wish to protect such devices and the privacy-related risks associated with the collection and use of data from such devices. This Insight explores each of these issues in turn. ...
Allens recognised for Deal of the Year and PPP of the Year at global awards
Lead partner for both projects David Donnelly acknowledged the teams behind the deals and commended their outstanding work during the uncertainty of the pandemic: 'We're delighted to be recognised ...
Antibody patent protection in Australia
Many of the top selling drugs in Australia are antibodies, all part of a global market estimated to reach US$140 billion this year. Recently, the US FDA (Food and Drug Administration) approved the ...
Expansion in scope of transactions subject to FIRB approval rules
In this Insight, we look at the changes and comment on what they mean for transactions. The changes to the SOCI Act also have operational implications for many businesses – which we will separately publish on. ...
Allens advises Pacific Equity Partners on sale of Lifehealthcare
'We again congratulate our long-standing client Pacific Equity Partners on another significant exit, this time in relation to the sale of its Lifehealthcare business, having advised PEP on the ...